Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNX-102 SL in fibromyalgia
NCT02829814Phase 3Terminated
- Sponsor
- Tonix Pharmaceuticals
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in fibromyalgia (FM) comparing Tonmya 2.8 mg with Placebo (2 arms). Primary endpoint: Weekly Mean Pain Score at Week 12. Started Jul 2016; status: terminated.
02
Drugs
Tonmya
03
Conditions
fibromyalgia (FM)
Beyond the preview
Go deeper on NCT02829814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829814.